Nuvectis Pharma (NVCT) Other financing activities (2021 - 2023)

Nuvectis Pharma has reported Other financing activities for 3 years, with the latest figure at $14000.0 in Q3 2023.

• Quarterly Other financing activities fell 97.5% year-over-year to $14000.0 in Q3 2023, while the trailing twelve-month figure through Dec 2023 was $11.2 million (down 34.43% YoY) and the FY2023 annual result came in at $11.2 million, down 30.05% from the prior year.
• Other financing activities eased to $14000.0 in Q3 2023 per NVCT's latest filing, from $10.5 million in the prior quarter.
• Over five years, Other financing activities peaked at $16.0 million in Q1 2022 and troughed at $14000.0 in Q3 2023.
• A 3-year average of $3.7 million and a median of $630500.0 in 2022 frame the typical range for Other financing activities.
• The widest YoY moves for Other financing activities: up 1954.12% in 2023, down 97.5% in 2023.
• Over 3 years, Other financing activities stood at $136000.0 in 2021, then surged by 311.03% to $559000.0 in 2022, then slumped by 97.5% to $14000.0 in 2023.
• According to Business Quant data, Other financing activities over the past three periods registered $14000.0, $10.5 million, and $702000.0 for Q3 2023, Q2 2023, and Q1 2023 respectively.